Navigation Links
Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial
Date:1/17/2008

SAN DIEGO, Jan. 17 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) today announced the receipt of a $2.1 million cash payment from AnGes MG, Inc. for costs associated with the ongoing Allovectin-7(R) Immunotherapeutic for Metastatic Melanoma (AIMM) Phase 3 trial.

AnGes is funding the Phase 3 pivotal trial of Allovectin-7(R) under a previously announced collaborative agreement through a scheduled series of cash payments and equity investments totaling $22.6 million, for which AnGes received exclusive marketing rights in Japan and other key Asian countries, and also will receive certain royalties for sales in the United States and European countries. Vical is conducting the trial in accordance with a Special Protocol Assessment (SPA) completed with the U.S. Food and Drug Administration (FDA).

The payment was triggered by utilization of previous cash balances, reflecting progress in the trial. The cash payment was received as anticipated in late December, and will be included in Vical's year-end 2007 cash balances, consistent with the company's guidance of a projected 2007 net cash burn of $27 million to $32 million. Revenue related to the cash payment will be deferred and matched to trial expenses as they are incurred.

About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the
'/>"/>

SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
2. New Study Shows Listeria Vaccine for Cervical Cancer Found Safe
3. Vical Demonstrates Dose-sparing of Protein-based H5N1 Influenza Vaccine With Vaxfectin(TM) Adjuvant
4. The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy
5. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
6. Spine Institute of Louisiana Offers Cervical Spine Motion Preservation as an Alternative to Fusion Surgery
7. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
8. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
9. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
10. Fovea Pharmaceuticals Receives Orphan Drug Designation from EC for RdCVF for the Treatment of Retinitis Pigmentosa
11. Hawaii Biotech Receives Allowance to Perform West Nile Vaccine Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 11, 2014  Major advances in radiation therapy ... being highlighted in a three-day Oncology Summit taking ... July, 2014.  Renowned national and international cancer experts from ... and exchange knowledge on modern technologies making treatment ... The Summit will address a ...
(Date:7/10/2014)... 11. Juli 2014  Dilon Technologies, ... die molekulare Bildgebung, einschließlich molekularer Bildgebung ... CE-Zulassung für sein Navigator ® -Gamma-Sondensystem ... das Produkt jetzt europaweit vertreiben. Dilon ... der europäischen Länder ausgedehnt und bereits ...
(Date:7/10/2014)...  The U.S. Department of Health and Human Services ... (UH) Case Medical Center Seidman Cancer Center totaling $4.7 ... improving care for patients with complex cancer. ... a unique model developed at UH to enhance care ... or demonstrated need for high health care utilization.  ...
Breaking Medicine Technology:Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4
... New to Antiretroviral Therapy Respond ... Similarly to Men and ... once-daily or twice-daily dosing of Abbott,s (NYSE:,ABT) protease inhibitor Kaletra(R) ... amount of HIV-1),and improving the immune system (increasing CD4 cells) ...
... a,biopharmaceutical company engaged in the discovery and development ... announced today,that Genentech, a collaborator, has moved a ... into a phase 1 clinical trial,that has begun ... and tolerability of both single and multiple doses ...
Cached Medicine Technology:Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 2Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 3Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 4Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 5Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 6Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 7Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 8Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial 2Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial 3
(Date:7/10/2014)... 10, 2014 CBPartners, a global leader ... launched a new website. The redesigned site boasts ... access to the firm’s thought pieces, blog posts, and ... platform to showcase our insights, capabilities, and to provide ... Chief Executive Officer, Cyrus Chowdhury. “An enhanced online ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Parker ... protecting the rights of victims injured by defective ... a lawsuit over allegations that the woman’s hidden, ... a power morcellator used during a routine laparoscopic ... against Richard Wolf Medical Instruments Corporation over its ...
(Date:7/10/2014)... 10, 2014 (HealthDay News) -- Nature, not nurture, may ... individual chimpanzees, a new study finds. "As is ... to cognitive [thinking] abilities in chimpanzees," William Hopkins of ... in a news release from the journal Current ... into the evolution of intelligence in humans, Hopkins, team ...
(Date:7/10/2014)... Kristen Fischer HealthDay Reporter ... help ease the hot flashes that often accompany menopause, new ... than 50 percent of menopausal women, said Dr. Taraneh Shirazian, ... at the Icahn School of Medicine at Mount Sinai Hospital ... more than 10 hot flashes a day, and she added ...
(Date:7/10/2014)... announcement that the "Mississippi Baby," believed to have been ... have detectable levels of the virus, the Elizabeth Glaser ... but remains hopeful that the scientific breakthrough that allowed ... than two years will continue to help researchers understand ... , "Although we had high hopes that the ...
Breaking Medicine News(10 mins):Health News:CBPartners Announces New Website 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 3Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 4Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 5Health News:Like Humans, Chimps' Smarts May Rely on Genes 2Health News:Losing Weight May Ease Hot Flashes, Study Finds 2Health News:Losing Weight May Ease Hot Flashes, Study Finds 3Health News:Despite setback, 'Mississippi Baby' represents significant breakthrough in effort to end AIDS 2
... cord by a couple of minutes can have a beneficial effect ... developed countries the tendency of doctors is to cut the umbilical ... problems and allow the mother to hold her baby without delay. ... time ensues before the umbilical cord is severed. ,The ...
... Public Health has been established at Kattankulathur, off Chennai, capital ... will be functioning as part of the SRM Medical College ... SRM University, said the School of Public Health had been ... from the US and the other from the UK. ...
... is a mother’s prayers answered. Five years back Timothy Bingham ... named// it after him- the Bingham syndrome. ,The boy ... like attacks, which rendered him totally paralyzed. It left him in ... of his eyes. ,Yet light has finally broken through ...
... ‘mild, mellow and giggling’ and ‘loved-up with a trippy edge’. ... regular party clubber// in UK’s hot nightspots. , ... by vets. Yet these are now increasingly offered ... , The rocketing use of these drugs have forced UK’s ...
... smoking is well known. But there is one more effect ... you look old, when you are actually// not. It has ... ,Dermatology researchers in the U.S. investigated the effects ... to sunlight. The study observed 82 people who smoked and ...
... paucity of anesthesiologists in the province of Ontario, evident in ... tide over such a situation, Ontario has created two additional ... times for patients. This strategy has proved its weight in ... time tested measure to improve patient care. ...
Cached Medicine News:Health News:New School of Public Health in Chennai 2
... precise and accurate Measurements! ,Patients are impressed ... examination when they see the doctor is ... - after only 5 minutes of proper ... proficient in the operation of this instrument ...
Great for small incisions and excision needs...
Multi-sided, Sharp all around...
...
Medicine Products: